rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2007-3-1-48-54rpcardio-385Research ArticlePOINT OF VIEWТОЧКА ЗРЕНИЯMICROCIRCULATORY ISCHEMIA AND STATINS: LESSONS OF INTERVENTION CARDIOLOGYМИКРОЦИРКУЛЯТОРНАЯ ИШЕМИЯ И СТАТИНЫ: УРОКИ ИНТЕРВЕНЦИОННОЙ КАРДИОЛОГИИАлександровАн. А.AlexandrovAn. A.

Отдел кардиологии Эндокринологического научного центра 

Department of Cardiology, Endocrinology Scientific Center

ЧукаеваИ. И.TchukaevaI. I.

Отдел кардиологии Эндокринологического научного центра

Department of Cardiology, Endocrinology Scientific Center

РАМН, МоскваРоссияRussian Academy of Medical Sciences, MoscowRussian Federation200726122015314854Copyright © Alexandrov A.A., Tchukaeva I.I., 20152015Александров А.А., Чукаева И.И.Alexandrov A.A., Tchukaeva I.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/385

Review is devoted to the pathogenesis of microcirculatory ischemia. Microcirculatory dysfunction has been identified in different groups of patients including syndrome X, diabetes mellitus 2 type, coronary heart disease. In coronary patients after transluminal angioplasty microcirculatory dysfunction is the reason of phenomenon of “non-reflow”. In result the procedure of revascularization is less effective. Therapy by statins can be beneficial for patients with microcirculatory ischemia.

Обзор посвящен современным представлениям о патогенезе микроциркуляторной ишемии. Согласно приведенным данным, микрососудистая дисфункция имеет место у различных категорий больных, в том числе больных с кардиальным синдромом Х, сахарным диабетом, коронарной болезнью сердца. У больных ишемичской болезнью сердца после транслюминальной ангиопластики микрососудистая дисфункция становится причиной развития феномена «non-reflow» («невосстанавливающегося кровотока»), что обусловливает низкую эффективность вмешательств по реваскуляризации миокарда. Особое внимание уделено результатам исследований эффективности статинов по коррекции микрососудистой дисфункции у различных категорий больных.

ишемическая болезнь сердцамикроциркуляторная ишемиятранслюминальная ангиопластикастатиныischemic heart diseasemicrocirculatory ischemiatransluminal angioplastystatinsReferencesDeWood MA, Spores J, Notske R et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med, 1980; 303: 897-902.DeWood MA, Spores J, Notske R et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med, 1980; 303: 897-902.Wtazume H, Iwama T, Kubo I, et al. No-reflow phenomenon during percutaneous transluminal coronary angioplasty. Am Heart J, 1988; 116: 211-215.Wtazume H, Iwama T, Kubo I, et al. No-reflow phenomenon during percutaneous transluminal coronary angioplasty. Am Heart J, 1988; 116: 211-215.Aiello EA, Jabr Rl, Cole WC, Arrhythmia and delayed recovery of cardiac action potential during reperfusion after ischemia: role of oxygen radical-induced no-reflow phenomenon. Circ Res., 1995;77: 153-162.Aiello EA, Jabr Rl, Cole WC, Arrhythmia and delayed recovery of cardiac action potential during reperfusion after ischemia: role of oxygen radical-induced no-reflow phenomenon. Circ Res., 1995;77: 153-162.Ho H, Maruyama A, Iwakura K, et al. Clinical implications of the "no reflow" phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996; 93; 223-228.Ho H, Maruyama A, Iwakura K, et al. Clinical implications of the "no reflow" phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation. 1996; 93; 223-228.Marzilli M, Oliozheni E, Marraccini P, et al. Primary coronary angioplasty in acute myocardial infarction: clinical correlates of the "no reflow" phenomenon. Int J Cardiol. I998; 65(suppl I): s23-s28.Marzilli M, Oliozheni E, Marraccini P, et al. Primary coronary angioplasty in acute myocardial infarction: clinical correlates of the "no reflow" phenomenon. Int J Cardiol. I998; 65(suppl I): s23-s28.Monshima 1, Sonc T, Okumura K, et al. Angiographic no-rcflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol., 2000; 36: 1202-1209.Monshima 1, Sonc T, Okumura K, et al. Angiographic no-rcflow phenomenon as a predictor of adverse long-term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol., 2000; 36: 1202-1209.DiMario C, Moses JW, Anderson TJ, et al. Randomize comparison of elective stent implantation and coronary baloon angioplasty guided by online quantitative angiograph and intracoronary doppler. Circulation, 2000; 102: 2930-7.DiMario C, Moses JW, Anderson TJ, et al. Randomize comparison of elective stent implantation and coronary baloon angioplasty guided by online quantitative angiograph and intracoronary doppler. Circulation, 2000; 102: 2930-7.Albertal M., Regar E, Van Langenhove G, et al. on behalf of the DE￾BATE investigators. Flow velocity and predictors of suboptimal coronary flow velocity reserve after coronary balloon angioplasty. Eur Heart J., 2002; 23: 133-8.Albertal M., Regar E, Van Langenhove G, et al. on behalf of the DE￾BATE investigators. Flow velocity and predictors of suboptimal coronary flow velocity reserve after coronary balloon angioplasty. Eur Heart J., 2002; 23: 133-8.Nishida T, Di Mario C, Kern MJ et al. Impact of final coronary flow velocity reserve on late outcome following stent implantation. Eur Heart J., 2002; 23: 331-40.Nishida T, Di Mario C, Kern MJ et al. Impact of final coronary flow velocity reserve on late outcome following stent implantation. Eur Heart J., 2002; 23: 331-40.Kloner RA, Ganote CE, Jennings RB. The «no-reflow» phenomenon after temporary coronary occlusion in the dog. J Clin Invest.,1974; 54: 1496-1508.Kloner RA, Ganote CE, Jennings RB. The «no-reflow» phenomenon after temporary coronary occlusion in the dog. J Clin Invest.,1974; 54: 1496-1508.Humphrey SM, Gavin JB, Herdson PB. Catecholamine-depletion and the no-reflow phenomenon in anoxic and ischaemic rat hearts. J Mol Cell Cardiol, 1982; 14: 151-161.Humphrey SM, Gavin JB, Herdson PB. Catecholamine-depletion and the no-reflow phenomenon in anoxic and ischaemic rat hearts. J Mol Cell Cardiol, 1982; 14: 151-161.Humphrey SM, Seelye RN, Gavin JB. The influence of adenosine on the no-reflow phenomenon in anoxic and ischaemic hearts. Pathophysiology, 1982; 14: 129-133.Humphrey SM, Seelye RN, Gavin JB. The influence of adenosine on the no-reflow phenomenon in anoxic and ischaemic hearts. Pathophysiology, 1982; 14: 129-133.Westin M., Heden P. Calcitonin gene-related peptide delays the no-reflow enomenon in the rat island flap. Ann Plast Surg., 1988; 21: 329- 334.Westin M., Heden P. Calcitonin gene-related peptide delays the no-reflow enomenon in the rat island flap. Ann Plast Surg., 1988; 21: 329- 334.Topol El, Mark DB; Lincoff AM et al. Outcomes at I year and economic implications of platelet glycoprotein lib/IlIa blockade in patients undergoing coronary stenting: results from a multicentre randornised trial. EPISTENT Investigators. Evaluation of Platelet lib/IlIa Inhibitor for Stenting. Lancet, 1999; 354: 2019-24.Topol El, Mark DB; Lincoff AM et al. Outcomes at I year and economic implications of platelet glycoprotein lib/IlIa blockade in patients undergoing coronary stenting: results from a multicentre randornised trial. EPISTENT Investigators. Evaluation of Platelet lib/IlIa Inhibitor for Stenting. Lancet, 1999; 354: 2019-24.Neumann FI, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schornig A. Effect of glycoprotein lIb/IlIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J. Am CoIl Cardiol., 1999; 34: 1420-6.Neumann FI, Zohlnhofer D, Fakhoury L, Ott I, Gawaz M, Schornig A. Effect of glycoprotein lIb/IlIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J. Am CoIl Cardiol., 1999; 34: 1420-6.Komamura K, Kitakaze M, Nishida K, et al. Progressive decreases in coronary vein flow during reperfusion m acute myocardial infarction: clinical documentation of the no reflow phenomenon after successful thrombolysis. J Am Coll Cardiol, 1994; 24: 370-377.Komamura K, Kitakaze M, Nishida K, et al. Progressive decreases in coronary vein flow during reperfusion m acute myocardial infarction: clinical documentation of the no reflow phenomenon after successful thrombolysis. J Am Coll Cardiol, 1994; 24: 370-377.Takahashi T, Anzai T, Yoshikawa T, et al. Absence of preinfarction angina ia associated with a risk of no-ieflow phenomenon after primary coronary angioplasty for a first anterior wall acute myocardial infarction. Int J Cordiol. 2000; 75: 253-260.Takahashi T, Anzai T, Yoshikawa T, et al. Absence of preinfarction angina ia associated with a risk of no-ieflow phenomenon after primary coronary angioplasty for a first anterior wall acute myocardial infarction. Int J Cordiol. 2000; 75: 253-260.Kemp НК Jr. Syndrome-Х revisited. J Am Coll Cardiol, 1991; 17: 507- 508.Kemp НК Jr. Syndrome-Х revisited. J Am Coll Cardiol, 1991; 17: 507- 508.Rosenson R.S. Statin therapy: new therapy for cardiac microvascular dysfunction. Eur. Heart J., 2003; 24: 1993-1994.Rosenson R.S. Statin therapy: new therapy for cardiac microvascular dysfunction. Eur. Heart J., 2003; 24: 1993-1994.Cannon R.O., Epstein S.E. “Microvascular angina” as a cause of chest pain with angiographically normal coronary arteries. Am. J. Cardiol, 1988; 61: 1338.Cannon R.O., Epstein S.E. “Microvascular angina” as a cause of chest pain with angiographically normal coronary arteries. Am. J. Cardiol, 1988; 61: 1338.Meyer C, Schwaiger M. Myocardial blood flow and glucose metabolism in diabetes mellitus. Am J Cardiol., 1997;80(3A): 94A-101A.Meyer C, Schwaiger M. Myocardial blood flow and glucose metabolism in diabetes mellitus. Am J Cardiol., 1997;80(3A): 94A-101A.Kollros PR, Konkle BA. Microvascular disease in diabetes mellitus. J. Cardiovasc Risk, 1997; 4: 70-5.Kollros PR, Konkle BA. Microvascular disease in diabetes mellitus. J. Cardiovasc Risk, 1997; 4: 70-5.Ceriello A, Giacomello R, Stel G, et al. Hyperglicemia-induced thrombin formation in diabetes. Diabetes, 995; 44: 924-8.Ceriello A, Giacomello R, Stel G, et al. Hyperglicemia-induced thrombin formation in diabetes. Diabetes, 995; 44: 924-8.Wiernsperger N.F., Bouskela E. Microcirculation in insulin resistance and diabetes: more than just a complication. Diabetes Metab., 2003; 23: 6S77-6S87.Wiernsperger N.F., Bouskela E. Microcirculation in insulin resistance and diabetes: more than just a complication. Diabetes Metab., 2003; 23: 6S77-6S87.Kayikcioglu М, Payzin S, Yavuzgil O. et al. Benefits of statin treatment in cardiac syndrome-Х. Еur Неагt J., 2003; 24: 1999-2005.Kayikcioglu М, Payzin S, Yavuzgil O. et al. Benefits of statin treatment in cardiac syndrome-Х. Еur Неагt J., 2003; 24: 1999-2005.Fabian E, Varga А. Effect of simvastatin therapy on endothelial function of hypercholesteremic patients with syndrome-Х. Orv Hetil, 2002; 143: 2067-71.Fabian E, Varga А. Effect of simvastatin therapy on endothelial function of hypercholesteremic patients with syndrome-Х. Orv Hetil, 2002; 143: 2067-71.Lee CH, de Feyter P, SerruysPW, Saia F, Lemos PA, Goedhart D, Soares PR, Umans V A W, Ciccone M, Cortellaro M. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS). Heart, 2004; 90: 1156-1161.Lee CH, de Feyter P, SerruysPW, Saia F, Lemos PA, Goedhart D, Soares PR, Umans V A W, Ciccone M, Cortellaro M. Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS). Heart, 2004; 90: 1156-1161.Walter DH, Fichtlscherer S, Britten MB et al. Initiation of tatin therapy immediately after stent implantation: profound benefit in patients with acute coronary syndromes (Abstr). Circulation, 2000; 244.Walter DH, Fichtlscherer S, Britten MB et al. Initiation of tatin therapy immediately after stent implantation: profound benefit in patients with acute coronary syndromes (Abstr). Circulation, 2000; 244.

The authors declare that there are no conflicts of interest present.